Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer (TRIBECA)

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Sorrento Therapeutics, Inc.
Sponsor:
Information provided by (Responsible Party):
Sorrento Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT02064829
First received: February 14, 2014
Last updated: September 2, 2014
Last verified: September 2014

February 14, 2014
September 2, 2014
March 2014
April 2015   (final data collection date for primary outcome measure)
  • Maximum observed concentration of paclitaxel (Cmax) [ Time Frame: Predose: 30 min; During infusion: 30 min; Post-infusion: 5, 10, 15, 30, and 45 min, and 1, 1.5, 2, 4, 7, 10, 24, 30 and 48 or 72 hr ] [ Designated as safety issue: No ]
  • Area under the concentration-time curve from time zero to infinite time of paclitaxel (AUC 0-inf) [ Time Frame: Predose: 30 min; During infusion: 30 min; Post-infusion: 5, 10, 15, 30, and 45 min, and 1, 1.5, 2, 4, 7, 10, 24, 30 and 48 or 72 hr ] [ Designated as safety issue: No ]
Maximum observed concentration of paclitaxel (Cmax) [ Time Frame: Periods 1 and 2 - Predose; During infusion: 15 min and 30 min; Post-infusion: 15 min, 30 min, 1 h, 1.5 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT02064829 on ClinicalTrials.gov Archive Site
Not Provided
  • Area under the concentration-time curve from time zero to time t of paclitaxel (AUC 0-t) [ Time Frame: Periods 1 and 2 - Predose; During infusion: 15 min and 30 min; Post-infusion: 15 min, 30 min, 1 h, 1.5 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h ] [ Designated as safety issue: No ]
  • Area under the concentration-time curve from time zero to infinite time of paclitaxel (AUC 0-inf) [ Time Frame: Periods 1 and 2 - Predose; During infusion: 15 min and 30 min; Post-infusion: 15 min, 30 min, 1 h, 1.5 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h ] [ Designated as safety issue: No ]
  • Number of participants affected by treatment-emergent adverse events coded using the Medical Dictionary for Regulatory Activities (MedDRA) [ Time Frame: Up to 30 days after the last dose of study drug ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer
An Open-label, Randomized, Multi-center, Single-Dose, 2-Sequence, 2-Period, Crossover, Comparative Bioequivalence Study of IG-001 (Cb-paclitaxel) 260 mg/m2 Versus Nab-paclitaxel 260 mg/m2 Administered Intravenously With an Open-Label Extension of IG-001 in Patients With Metastatic or Locally Recurrent Breast Cancer

The purpose of this study is to demonstrate bioequivalence of IG-001 versus nab-paclitaxel in female patients with metastatic or locally recurrent breast cancer. In addition, the study will compare the safety and tolerance of IG-001 and nab-paclitaxel during the bioequivalence 2-period crossover portion of the study. The study will also evaluate the long-term safety of IG-001 over repeated cycles, up to 4 additional cycles of administration.

This study is designed to compare the pharmacokinetics (PK) of IG-001 and nab-paclitaxel in patients with metastatic or locally recurrent breast cancer. Patients meeting the eligibility criteria will be randomized to determine which drug is administered first.

  • Patients randomized to Group 1 will receive a single dose of IG-001 (Period 1) followed 3 weeks later by a single dose of nab-paclitaxel (Period 2).
  • Patients randomized to Group 2 will receive a single dose of nab-paclitaxel (Period 1) followed 3 weeks later by a single dose of IG-001 (Period 2).

Blood samples for PK analysis will be taken at specified times before, during, and after the infusion of each drug in Periods 1 and 2. Following successful completion of Period 1 and Period 2, patients may be eligible for up to 4 additional cycles of treatment with IG-001 in the extension study.

Safety will be monitored throughout the study.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Metastatic Breast Cancer
  • Locally Recurrent Breast Cancer
  • Drug: Nab-paclitaxel
    260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
    Other Names:
    • Paclitaxel albumin-bound particles for injectable suspension
    • nab-paclitaxel
  • Drug: IG-001
    260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
    Other Names:
    • Paclitaxel polymeric micelles for injectable suspension
    • Genexol-PM
    • Cynviloq
  • Active Comparator: Reference Drug - Nab-paclitaxel
    260 mg/m2 administered intravenously over 30 minutes on Day 1
    Intervention: Drug: Nab-paclitaxel
  • Experimental: Test Drug - IG-001
    260 mg/m2 administered intravenously over 30 minutes on Day 1
    Intervention: Drug: IG-001
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
112
June 2015
April 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Breast cancer patient who

    1. Has histologically confirmed diagnosis of breast cancer.
    2. Has stage IV or locally recurrent breast cancer per the American Joint Committee on Cancer Staging Manual,7th edition.
    3. Has failed any single agent or combination chemotherapy for metastatic or locally recurrent disease.
    4. Has agreed to participate in the study and signed the informed consent form prior to participation in any study activities.
  2. Sex and Age: Female ≥ 30 years of age.
  3. Body surface area (BSA) that is within 1.2 to 2.2 m2, calculated using the Mosteller or DuBois Formula. The same formula must be used consistently for any given patient.
  4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
  5. Sitting blood pressure (BP) and heart rate (HR): Systolic and diastolic BP (SBP/DBP) and HR in the normal range or no worse than Grade 1 abnormality by the Common Terminology Criteria for Adverse Events version 4, as amended (CTCAE).
  6. Hematology/chemistry: Patient has adequate hematological, renal, and hepatic function as defined by the following Screening laboratory values obtained within 7 days prior to randomization and assessed based on local labs (patients should not have received a transfusion within 7 days before the Screening laboratory assessments):

    1. Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3 (1.5x10^9/L)
    2. Platelet count ≥ 100,000 cells/mm3 (100x10^9/L)
    3. Hemoglobin ≥ 9 g/dL
    4. Serum creatinine ≤ 1.5 x the upper limit of normal (ULN)
    5. Total bilirubin ≤ 1.25 x ULN
    6. AST (SGOT) ≤ 2.5 x ULN
    7. ALT (SGPT) ≤ 2.5 x ULN
  7. All other clinical laboratory values deemed normal or not clinically significant by the Principal Investigator/Sub-Investigator.
  8. Pregnancy status: Patients must be non-pregnant (due to teratogenic or abortifacient effects of paclitaxel) from 30 days prior to randomization until 30 days after the last dose of study drug. Women who are not post-menopausal ≥ 52 weeks or surgically sterilized (e.g., hysterectomy, bilateral oophorectomy, bilateral tubal ligation) are considered of childbearing potential. For women of childbearing potential (WOCBP), a serum pregnancy test (β-hCG) must be negative at Screening, and a urine pregnancy test must be negative prior to each dose of study drug.
  9. Breastfeeding: Patients must not be lactating or breastfeed during the study. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding must be discontinued prior to the first dose of study drug.
  10. Contraception: If sexually active, WOCBP must agree to use contraception considered adequate and appropriate by the Investigator throughout the course of the study and for 30 days after she receives the last dose of study drug.
  11. Able and willing to adhere to all protocol requirements and study procedures throughout the study.
  12. Ability to comprehend and be informed of the nature of the study, as assessed by study clinic staff.

Exclusion Criteria:

  1. Patients with a history of other malignancies, except for adequately treated nonmelanoma skin cancer, curatively treated in-situ carcinoma of the cervix, in-situ carcinoma of the breast or other solid tumors with no evidence of recurrence for ≥ 5 years.
  2. Patients who have previously received a taxane within the 30 days prior to randomization.
  3. Patients who have not completely recovered from any toxicities from previous chemotherapy, hormone therapy, immunotherapy, or radiotherapies Grade 1 or higher by CTCAE, with the exception of alopecia.
  4. Prior chemotherapy must be completed at least 30 days prior to randomization (42 days for mitomycin C or nitrosoureas). Prior immunotherapy, prior anti-tumor hormonal therapy, and prior radiotherapy must be completed at least 14 days prior to randomization. Radiotherapy is not allowed during the study. Administration of other chemotherapy, immunotherapy, or anti-tumor hormonal therapy during the study is not allowed.
  5. Patient had major surgery within 30 days prior to randomization, or patient has not recovered from prior major surgery.
  6. Sensory / Peripheral neuropathy of Grade 2 or higher by CTCAE at Screening.
  7. Patients with known brain metastases, with the exception of patients who have completed surgery and/or radiotherapy at least 30 days prior to randomization, have completed any steroids as treatment for the metastases at least 30 days prior to randomization, and who are currently asymptomatic.
  8. Known history or presence of any clinically significant disease or condition other than cancer unless determined as not clinically significant by the Investigator.
  9. History of difficulty with vascular access.
  10. Known history or presence of:

    1. Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C
    2. Alcohol or drug abuse or dependence within one year prior to randomization
    3. Hypersensitivity or idiosyncratic reaction to paclitaxel, its excipients, and/or related substances, including, albumin and PEG.
  11. Patients may not participate in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or the use of investigational devices with therapeutic intent within 30 days prior to randomization and while enrolled in this study.
  12. Use of any CYP2C8 and CYP3A4 inhibitor (e.g., ketoconazole and other imidazole antifungals, erythromycin, fluoxetine, gemfibrozil, cimetidine, ritonavir, saquinavir, indinavir, and nelfinavir) or inducer (e.g., rifampicin, carbamazepine, phenytoin, efavirenz, and nevirapine) in the previous 14 days before randomization until the last PK sample is obtained in the study.
  13. Acute active infection requiring treatment within 14 days prior to randomization.
  14. Patients with any significant history of non-compliance or inability to reliably grant informed consent.
Female
30 Years and older
No
Contact: Sorrento Therapeutics Clinical Trial Information tribecastudy@sorrentotherapeutics.com
United States,   Bulgaria,   Moldova, Republic of,   Singapore
 
NCT02064829
STI-102
No
Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc.
Not Provided
Not Provided
Sorrento Therapeutics, Inc.
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP